Esophageal Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Apr 15, 2004; 10(8): 1098-1102
Published online Apr 15, 2004. doi: 10.3748/wjg.v10.i8.1098
Table 2 Results for CRT and IMRT in five upper esophageal cancer patients(mean±SD)
StuctureParameterCRT3F IMRT5F IMRT7F IMRT9F IMRT
PTV1Mean dose (Gy)73.0 ± 3.074.9 ± 3.874.2 ± 2.373.9 ± 2.074.1 ± 1.5
SD (%)6.3 ± 3.76.7 ± 2.76.0 ± 2.05.7 ± 2.16.0 ± 1.7
D95 (Gy)67.2 ± 0.067.2 ± 0.067.2 ± 0.067.2 ± 0.067.2 ± 0.0
CI0.47 ± 0.160.59 ± 0.180.70 ± 0.040.74 ± 0.060.75 ± 0.07
PTV2Mean dose (Gy)65.3 ± 4.460.0 ± 2.359.3 ± 1.458.4 ± 1.858.4 ± 2.0
SD (%)11.6 ± 3.89.2 ± 1.88.8 ± 1.58.5 ± 1.98.6 ± 1.8
D95 (Gy)52.4 ± 3.351.2 ± 2.850.8 ± 3.450.5 ± 3.351.2 ± 2.9
CI0.52 ± 0.080.46 ± 0.110.64 ± 0.060.67 ± 0.070.68 ± 0.08
LungMean dose (Gy)12.4 ± 1.711.1 ± 1.210.8 ± 1.310.7 ± 1.310.9 ± 1.2
V20 (%)24.7 ± 2.822.1 ± 1.722.4 ± 0.723.2 ± 1.623.8 ± 1.7
V30 (%)18.6 ± 2.915.1 ± 1.615.0 ± 1.913.5 ± 2.213.5 ± 3.2
Spinal cordMaximum dose (Gy)40.9 ± 2.756.9 ± 7.243.9 ± 1.043.3 ± 0.842.0 ± 1.5